
201 - 500 employees
Founded 2015
🧬 Biotechnology
🏥 Healthcare
💊 Pharmaceuticals
💰 $140M Post-IPO Equity - Replimune Group on 2024-11
Biotechnology • Healthcare • Pharmaceuticals
Replimune is a clinical-stage biotechnology company focused on developing a new class of oncolytic immunotherapies intended to activate powerful, durable systemic anti-tumor immune responses. The company’s approach is to kill tumors locally, alter the tumor microenvironment, and ignite a full-body, tumor-specific immune response. Replimune is conducting clinical programs evaluating the safety and effectiveness of its investigational therapies in a range of solid tumors, both as single agents and in combination with other immunotherapies.
Selected: 🆕 Date Added.
🕒 October 7
Director leading claims analytics, commercial reporting, and data strategy for Replimune’s cancer immunotherapy business. Translating pharmaceutical data into executive insights and launch decisions.
🇺🇸 United States – Remote
💵 $201.5k - $260.5k / year
💰 $140M Post-IPO Equity - Replimune Group on 2024-11
⏰ Full Time
🔴 Lead
📉 Data Analyst
👻 Ghost score 0%
🕒 September 25
Medical publications director leading scientific communications for Replimune’s oncolytic cancer immunotherapies. Developing compliant publications, congress materials, and product-science insights across Medical Affairs.
🍂 Massachusetts – Remote
💵 $208k - $269k / year
💰 $140M Post-IPO Equity - Replimune Group on 2024-11
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 10%
🕒 September 16
Clinical scientist advancing oncology trials for Replimune’s oncolytic immunotherapy pipeline. Leading clinical documents, study execution, data analysis, and investigator collaboration.
🍂 Massachusetts – Remote
💵 $159k - $205.5k / year
💰 $140M Post-IPO Equity - Replimune Group on 2024-11
⏰ Full Time
🟠 Senior
🧪 Clinical Research
👻 Ghost score 0%
🕒 September 10
Regional Medical Science Liaison director leading field medical strategy and MSL teams. Supporting Replimune’s oncolytic immunotherapy development and cancer-care mission.
🍂 Massachusetts – Remote
💵 $256k - $331k / year
💰 $140M Post-IPO Equity - Replimune Group on 2024-11
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 1%
🕒 August 28
Operational Excellence Lead helping U.S. treatment centers adopt Replimune’s RP1 cancer therapy. Optimizing workflows, readiness, logistics, and multidisciplinary care coordination.
🍂 Massachusetts – Remote
💵 $170k - $218k / year
💰 $140M Post-IPO Equity - Replimune Group on 2024-11
⏰ Full Time
🟠 Senior
⚙️ Operations
👻 Ghost score 5%